Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabrecta in advanced hepatocellular carcinoma
NCT01737827Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
A Phase 2 trial of capmatinib in hepatocellular carcinoma (HCC), sponsored by Novartis. Started Mar 2013; status: terminated.
02
Drugs
capmatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01737827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01737827.